Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions

Immunology

Volumn 116, Issue 4, 2005, Pages 487-498

  Li, Bohua ^a,b   Wang, Hao ^a,b   Dai, Jianxin ^a   Ji, Junjie ^a   Qian, Weizhu ^a   Zhang, Dapeng ^a   Hou, Sheng ^a   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai CPGJ Research Institute   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CD3; First dose syndrome; Humanization; Immunosuppression; Monoclonal antibody

Indexed keywords

AMINO ACID; CHIMERIC ANTIBODY; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD3 12F6; OKT 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MITOGENICITY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD3; BINDING, COMPETITIVE; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MOLECULAR SEQUENCE DATA; MUROMONAB-CD3; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 28244439907     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02247.x     Document Type: Article

References (47)

1. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol 1998; 81:105-19.
2. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB. Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986; 41:572-8.
3. Hesse CJ, Heyse P, Stolk BJ, Balk AH, Jutte NH, Mochtar B, Weimar W. The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients. Transplant Proc 1990; 22:1772-3.
4. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17:615-20.
5. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321:522-5.
6. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7.
7. Woodle ES, Thistlethwaite JR, Jolliffe LK, Fucello AJ, Stuart FP, Bluestone JA. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation 1991; 52:361-8.
8. Gaston RS, Deierhoi MH, Patterson T et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39:141-8.
9. Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11:112-9.
10. Landegren U, Andersson J, Wigzell H. Mechanism of T lymphocyte activation by OKT3 antibodies. A general model for T cell induction. Eur J Immunol 1984; 14:325-8.
11. Looney RJ, Abraham GN. The Fc portion of intact IgG blocks stimulation of human PBMC by anti-T3. J Immunol 1984; 133:154-6.
12. Ceuppens JL, Meurs L, Van Wauwe JP. Failure of OKT3 monoclonal antibody to induce lymphocyte mitogenesis: a familial defect in monocyte helper function. J Immunol 1985; 134:1498-502.
13. Palacios R. Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody. Eur J Immunol 1985; 15:645-51.
14. Ceuppens JL, Bloemmen FJ, Van Wauwe JP. T cell unresponsiveness to the mitogenic activity of OKT3 antibody results from a deficiency of monocyte Fc gamma receptors for murine IgG2a and inability to cross-link the T3-Ti complex. J Immunol 1985; 135:3882-6.
15. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997; 159:3613-21.
16. Xu D, Alegre ML, Varga SS et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000; 200:16-26.
17. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139:1369-74.
18. Coloma MJ, Hastings A, Wims LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Meth 1992; 152:89-104.
19. Adair JR, Athwal DS, Bodmer MW et al. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas 1994; 5:41-7.
20. Looney RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 1986; 136:1641-7.
21. Jones DH, Looney RJ, Anderson CL. Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. J Immunol 1985; 135:3348-53.
22. Perussia B, Dayton ET, Lazarus R, Fanning V, Trinchieri G. Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells. J Exp Med 1983; 158:1092-113.
23. Alegre ML, Collins AM, Pulito VL et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a 'humanized' OKT3 monoclonal antibody. J Immunol 1992; 148:3461-8.
24. Kabat EA, Wu TT, Reid-Miller M, Perry HM, Gottesman KS. Sequences of proteins of immunological interest, 4th edn. Washington DC: United States Department of Health and Human Services; 1987.
25. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332:563-4.
26. Kipriyanov SM, Little M. Generation of recombinant antibodies. Mol Biotechnol 1999; 12:173-201.
27. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86:10029-33.
28. Ohtomo T, Tsuchiya M, Sato K et al. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol Immunol 1995; 32:407-16.
29. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89:4285-9.
30. Pulito VL, Roberts VA, Adair JR et al. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J Immunol 1996; 156:2840-50.
31. Abramowicz D, Schandene L, Goldman M et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47:606-8.
32. Chatenoud L, Ferran C, Legendre C et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49:697-702.
33. Woodle ES, Thistlethwaite JR, Ghobrial IA, Jolliffe LK, Stuart FP, Bluestone JA. OKT3 F(ab′)2 fragments - retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 1991; 52:354-60.
34. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49:1117-23.
35. Schandene L, Gerard C, Crusiaux A, Abramowicz D, Velu T, Goldman M. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant Proc 1993; 25 (2 Suppl. 1):55-6.
36. Herbelin A, Abramowicz D, de Groote D, Naret C, Kreis H, Bach JF, Goldman M, Chatenoud L. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis. Transplantation 1999; 68:616-22.
37. Risso A, Smilovich D, Capra MC, Baldissarro I, Yan G, Bargellesi A, Cosulich ME. CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J Immunol 1991; 146:4105-14.
38. Bajorath J, Aruffo A. Molecular model of the extracellular lectin-like domain in CD69. J Biol Chem 1994; 269:32457-63.
39. Testi R, Phillips JH, Lanier LL. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C. J Immunol 1989; 142:1854-60.
40. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994; 12:456-65.
41. Biselli R, Matricardi PM, D'Amelio R, Fattorossi A. Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol 1992; 35:439-47.
42. Depper JM, Leonard WJ, Kronke M, Noguchi PD, Cunningham RE, Waldmann TA, Greene WC. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 1984; 133:3054-61.
43. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000; 59 (Suppl. 1):i109-i114.
44. Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140:3766-72.
45. Landegren U, Ramstedt U, Axberg I, Ullberg M, Jondal M, Wigzell H. Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies. J Exp Med 1982; 155:1579-84.
46. Van Seventer GA, Kuijpers KC, van Lier RA, de Groot ER, Aarden LA, Melief CJ. Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies. J Immunol 1987; 139:2545-50.
47. Anasetti C, Martin PJ, Storb R et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54:844-51.